{"schema_version":"secwatch.filing_event.v1","accession":"0001654954-22-016606","form_type":"8-K","ticker":"EDSA","cik":"0001540159","company_name":"Edesa Biotech, Inc.","filed_at":"2022-12-16T23:59:59+00:00","discovered_at":"2026-05-14T18:03:51.090929+00:00","generated_at":"2026-06-21T03:18:48.672992+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Edesa Biotech reports FY2022 net loss $17.55M; cash $7.09M; Phase 2 COVID ARDS positive","bullets":["Net loss of $17.55M ($1.05 loss per share) vs $13.34M ($1.10) in FY2021.","Total operating expenses decreased 22% to $18.37M from $23.68M year-over-year.","Cash and equivalents $7.09M at Sept 30, 2022; subsequent private placement raised ~$3.0M.","Phase 2 study of EB05 in COVID ARDS showed 84% reduction in risk of death vs placebo at 28 days.","Phase 2b dermatology study fully enrolled; topline data expected within 4 weeks."],"urls":{"canonical":"https://secwatch.observer/filing/0001654954-22-016606","json":"https://secwatch.observer/filing/0001654954-22-016606.json","markdown":"https://secwatch.observer/filing/0001654954-22-016606.md","text":"https://secwatch.observer/filing/0001654954-22-016606.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1540159/000165495422016606/0001654954-22-016606-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1540159/000165495422016606/edsa_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-21T03:18:48.672992+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"40c58881f90d875bca913c82fa270e9144fc0694","claim":"Edesa Biotech, Inc. reported fiscal year ended September 30, 2022 results: net income $17.55 million, or $1.05 per common share, EPS $1.05 per common share.","evidence_excerpt":"For the fiscal year ended September 30, 2022, Edesa reported a net loss of $17.55 million, or $1.05 per common share, compared to a net loss of $13.34 million, or $1.10 per common share, for the fiscal year ended September 30, 2021.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1540159/000165495422016606/0001654954-22-016606-index.htm","confidence":0.95,"family_label":"Earnings Releases","details":[{"label":"Period","value":"fiscal year ended September 30, 2022"},{"label":"Net income","value":"$17.55 million, or $1.05 per common share"},{"label":"EPS","value":"$1.05 per common share"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}